ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years
Matteo Ponzo
Matched on ORCID iD 0000-0002-0280-7989; OpenAlex author ID A5020097591. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 19
2021: 2 papers · 2022: 2 papers · 2023: none · 2024: 1 paper
Papers 5
- TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion. Co-author DOI 10.1136/jitc-2024-008898↗
- Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Co-author DOI 10.3390/cancers14174265↗
- Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers 2022, 14, 4265. Co-author DOI 10.3390/cancers14246160↗
- Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages. Co-author DOI 10.1016/j.jcmgh.2021.01.008↗
- Nucleolin Targeting by N6L Inhibits Wnt/β-Catenin Pathway Activation in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13122986↗
Closest collaborators
The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ilaria Cascone · 5 shared papers, 2021–2024 · strength 0.60
- Paper TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion. DOI 10.1136/jitc-2024-008898↗
- Paper Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. DOI 10.3390/cancers14174265↗
- Paper Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers 2022, 1… DOI 10.3390/cancers14246160↗
- Anaïs Debesset · 4 shared papers, 2021–2024 · strength 0.51
- Paper TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion. DOI 10.1136/jitc-2024-008898↗
- Paper Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. DOI 10.3390/cancers14174265↗
- Paper Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers 2022, 1… DOI 10.3390/cancers14246160↗
- José Laurent Cohen · 4 shared papers, 2021–2024 · strength 0.51
- Paper TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion. DOI 10.1136/jitc-2024-008898↗
- Paper Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. DOI 10.3390/cancers14174265↗
- Paper Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers 2022, 1… DOI 10.3390/cancers14246160↗
- Mounira Chalabi‐Dchar · 3 shared papers, 2021–2022 · strength 0.34
- Paper Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. DOI 10.3390/cancers14174265↗
- Paper Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers 2022, 1… DOI 10.3390/cancers14246160↗
- Paper Nucleolin Targeting by N6L Inhibits Wnt/β-Catenin Pathway Activation in Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers13122986↗
- Fabio Raineri · 3 shared papers, 2021–2022 · strength 0.34
- Paper Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. DOI 10.3390/cancers14174265↗
- Paper Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers 2022, 1… DOI 10.3390/cancers14246160↗
- Paper Nucleolin Targeting by N6L Inhibits Wnt/β-Catenin Pathway Activation in Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers13122986↗
- Philippe Bouvet · 3 shared papers, 2021–2022 · strength 0.34
- Paper Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. DOI 10.3390/cancers14174265↗
- Paper Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers 2022, 1… DOI 10.3390/cancers14246160↗
- Paper Nucleolin Targeting by N6L Inhibits Wnt/β-Catenin Pathway Activation in Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers13122986↗
- Rémy Nicolle · 3 shared papers, 2021–2022 · strength 0.32
- Paper Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. DOI 10.3390/cancers14174265↗
- Paper Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers 2022, 1… DOI 10.3390/cancers14246160↗
- Paper Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With … DOI 10.1016/j.jcmgh.2021.01.008↗
- Corinne Bousquet · 3 shared papers, 2021–2022 · strength 0.32
- Paper Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. DOI 10.3390/cancers14174265↗
- Paper Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers 2022, 1… DOI 10.3390/cancers14246160↗
- Paper Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With … DOI 10.1016/j.jcmgh.2021.01.008↗
- Christophe Tournigand · 2 shared papers, 2022 · strength 0.23
- Jerome F. Cros · 2 shared papers, 2021 · strength 0.20
- Paper Nucleolin Targeting by N6L Inhibits Wnt/β-Catenin Pathway Activation in Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers13122986↗
- Paper Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With … DOI 10.1016/j.jcmgh.2021.01.008↗
- Anne Couvelard · 1 shared paper, 2021 · strength 0.11
- Cindy Neuzillet · 1 shared paper, 2021 · strength 0.09
- Yvan Martineau · 1 shared paper, 2021 · strength 0.09
- Jérôme Raffenne · 1 shared paper, 2021 · strength 0.09
- Stéphane Pyronnet · 1 shared paper, 2021 · strength 0.09
- Rémi Samain · 1 shared paper, 2021 · strength 0.09
- Richard Tomasini · 1 shared paper, 2021 · strength 0.09
- Jérémy Nigri · 1 shared paper, 2021 · strength 0.09
- Christine Jean · 1 shared paper, 2021 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.